Shares of Inozyme Pharma Inc. (INZY) fell to a 52-week low, hitting a price level of just $2.37. This latest decline reflects a significant decline for the biopharmaceutical company, whose share price has plummeted nearly 40% over the past year. With a market capitalization of $165 million, InvestingPro analysis suggests the stock is currently undervalued, while analyst price targets range from $12 to $43. The 1-year change data paints a clear picture of the challenges facing Inozyme Pharma, as investors witnessed a -39.95% decline in the value of their holdings. The company, which specializes in developing treatments for rare metabolic disorders, is navigating a difficult market environment, which has led to this significantly low share price. Despite the challenges, InvestingPro the data shows that the company maintains a strong liquidity position with a current ratio of 7.68, although it spends money quickly. Three analysts recently revised their earnings estimates upward for the upcoming period.
In other recent news, Inozyme Pharma reported positive interim results from its ENERGY 1 trial and expanded access program, evaluating the investigational drug INZ-701. The treatment led to significant improvements in survival rates, heart function and a reduction in arterial calcifications. The company also completed an application for its ENERGY 3 trial, expecting pivotal data in early 2026. Inozyme received regulatory guidance for its pivotal ASPIRE trial, planning to start the trial in early 2026.
Inozyme saw several analyst upgrades, including Jefferies initiating a Buy rating and Piper Sandler increasing its target on Inozyme to $43 while maintaining an Overweight rating. HC Wainwright reiterated a Buy rating and a $14.00 price target on shares of Inozyme.
The company announced approximately $23.8 million remaining in its market share offering program, which was facilitated by Jefferies LLC. Inozyme plans to initiate a registration trial for INZ-701 in patients with calciphylaxis in 2025, pending regulatory approval and funding. These are among the recent developments in Inozyme Pharma’s ongoing efforts in the biopharmaceutical sector.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
